Excess body weight—including overweight and obesity—is a significant risk factor for cancer. Research from the American Cancer Society estimates that it contributes to approximately 5 percent of ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Researchers have found that fewer sessions of higher dose vaginal cuff brachytherapy work just as well as more frequent, lower-dose treatments for endometrial cancer patients.

Here are 5 important questions to ask if you’ve been told you have cervical dysplasia: ...

WHO proposed the global strategy to accelerate the elimination of cervical cancer as a public health problem, 1 which means 194 countries and regions have the responsibility to take action to ensure ...

1 The upcoming campaign and its subsequent integration into the routine immunisation programme is a testament to Nepal's dedication to public health and commitment to the Global Strategy for Cervical ...

Here are some things we got to know: Myth 1: Cervical cancer only affects older women. Fact: While the risk increases with age, women as young as 20 can develop cervical cancer, especially if they ...

January has been designated the Cervical Cancer Awareness Month. According to the World Health Organization, the intention is to raise awareness of cervical cancer and human papilloma virus (HPV) ...

Cervical cancer, the fourth most common cancer in women, is closely linked to persistent HPV infections. Early detection through Pap smears and HPV testing can significantly reduce mortality.

An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive cervical intraepithelial neoplasia grade 3 (CIN3), according to results from ...

Get Instant Summarized Text (Gist) A therapeutic vaccine targeting HPV16 showed promise in reducing high-grade precancerous cervical lesions in a Phase II clinical trial. Among 18 patients with ...